Published in Urology on September 01, 2002
Oridonin up-regulates expression of P21 and induces autophagy and apoptosis in human prostate cancer cells. Int J Biol Sci (2012) 1.02
Oridonin induces apoptosis and senescence by increasing hydrogen peroxide and glutathione depletion in colorectal cancer cells. Int J Mol Med (2012) 0.96
Therapeutic applications of herbal medicines for cancer patients. Evid Based Complement Alternat Med (2013) 0.90
Down-regulation of androgen-receptor and PSA by phytochemicals. Int J Oncol (2008) 0.78
PC-SPES. Urology (2003) 0.78
Oridonin induces G2/M cell cycle arrest and apoptosis via the PI3K/Akt signaling pathway in hormone-independent prostate cancer cells. Oncol Lett (2017) 0.75
The translational aspect of complementary and alternative medicine for cancer with particular emphasis on Kampo. Front Pharmacol (2015) 0.75
Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 12.44
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med (2015) 8.80
Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 6.51
Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA (2008) 5.66
Outcomes of localized prostate cancer following conservative management. JAMA (2009) 5.57
The double-edged sword of autophagy modulation in cancer. Clin Cancer Res (2009) 5.46
Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res (2011) 5.40
Risk profiles and treatment patterns among men diagnosed as having prostate cancer and a prostate-specific antigen level below 4.0 ng/ml. Arch Intern Med (2010) 3.85
Vitamin D, calcium supplementation, and colorectal adenomas: results of a randomized trial. J Natl Cancer Inst (2003) 3.44
Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am (2003) 3.44
Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res (2003) 3.25
Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol (2005) 3.15
Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. J Urol (2004) 3.06
Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int (2005) 3.06
Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 2.97
Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol (2002) 2.91
In vitro antiproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice. J Nutr Biochem (2005) 2.71
Gene signatures of progression and metastasis in renal cell cancer. Clin Cancer Res (2005) 2.67
Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol (2004) 2.65
Metabolic catastrophe as a means to cancer cell death. J Cell Sci (2007) 2.58
Tumor size does not predict risk of metastatic disease or prognosis of small renal cell carcinomas. J Urol (2008) 2.45
Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery. Eur Urol (2009) 2.41
Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer (2007) 2.38
Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int (2008) 2.35
Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. Eur Urol (2011) 2.10
Health ramifications of the obesity epidemic. Surg Clin North Am (2005) 2.10
Familial testicular torsion. J Urol (2011) 2.07
Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol (2005) 2.05
Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol (2005) 2.05
Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. J Clin Oncol (2004) 2.02
Growth inhibitory effect of low fat diet on prostate cancer cells: results of a prospective, randomized dietary intervention trial in men with prostate cancer. J Urol (2010) 1.94
Comparison of antioxidant potency of commonly consumed polyphenol-rich beverages in the United States. J Agric Food Chem (2008) 1.92
Tumor classification by tissue microarray profiling: random forest clustering applied to renal cell carcinoma. Mod Pathol (2005) 1.89
Secondary hormonal therapy for advanced prostate cancer. J Urol (2006) 1.86
Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin Cancer Res (2006) 1.86
Blackberry, black raspberry, blueberry, cranberry, red raspberry, and strawberry extracts inhibit growth and stimulate apoptosis of human cancer cells in vitro. J Agric Food Chem (2006) 1.84
p21 is a prognostic marker for renal cell carcinoma: implications for novel therapeutic approaches. J Urol (2007) 1.81
Male gender is a predictor of morbidity and age a predictor of mortality for patients undergoing gastric bypass surgery. Ann Surg (2002) 1.80
Limitations of MTT and MTS-based assays for measurement of antiproliferative activity of green tea polyphenols. PLoS One (2010) 1.77
Cytoreductive nephrectomy for kidney cancer with sarcomatoid histology--is up-front resection indicated and, if not, is it avoidable? J Urol (2009) 1.75
Risk of harm among gamblers in the general population as a function of level of participation in gambling activities. Addiction (2006) 1.75
Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol (2007) 1.75
Ganoderma lucidum causes apoptosis in leukemia, lymphoma and multiple myeloma cells. Leuk Res (2006) 1.74
Key transmission parameters of an institutional outbreak during the 1918 influenza pandemic estimated by mathematical modelling. Theor Biol Med Model (2006) 1.72
Prognostic significance of venous thrombus in renal cell carcinoma. Are renal vein and inferior vena cava involvement different? J Urol (2004) 1.70
Prognostic relevance of capsular involvement and collecting system invasion in stage I and II renal cell carcinoma. BJU Int (2007) 1.69
Characterization of human fibrocytes as circulating adipocyte progenitors and the formation of human adipose tissue in SCID mice. FASEB J (2005) 1.68
Prognostic impact of tumor size on pT2 renal cell carcinoma: an international multicenter experience. J Urol (2007) 1.67
Comparisons of percent equol producers between prostate cancer patients and controls: case-controlled studies of isoflavones in Japanese, Korean and American residents. Jpn J Clin Oncol (2004) 1.65
Smoking negatively impacts renal cell carcinoma overall and cancer-specific survival. Cancer (2011) 1.64
Prognostic value of microvascular invasion in predicting the cancer specific survival and risk of metastatic disease in renal cell carcinoma: a multicenter investigation. J Urol (2011) 1.63
Tumor biology and prognostic factors in renal cell carcinoma. Oncologist (2011) 1.62
Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGET-CABG) study. Circ Cardiovasc Interv (2012) 1.61
Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. Clin Cancer Res (2007) 1.61
Histologic evaluation of metastases in renal cell carcinoma with sarcomatoid transformation and its implications for systemic therapy. Cancer (2010) 1.61
Isolation and identification of strawberry phenolics with antioxidant and human cancer cell antiproliferative properties. J Agric Food Chem (2008) 1.61
Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group. Clin Cancer Res (2006) 1.60
Use of American Society of Anesthesiologists physical status classification to assess perioperative risk in patients undergoing radical nephrectomy for renal cell carcinoma. Urology (2004) 1.60
Bioavailability of ellagic acid in human plasma after consumption of ellagitannins from pomegranate (Punica granatum L.) juice. Clin Chim Acta (2004) 1.60
Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J Urol (2005) 1.60
Treatment of organ confined prostate cancer with third generation cryosurgery: preliminary multicenter experience. J Urol (2003) 1.60
Dominant B cell epitope from NY-ESO-1 recognized by sera from a wide spectrum of cancer patients: implications as a potential biomarker. Int J Cancer (2005) 1.59
Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J Urol (2003) 1.59
Intraoperative thrombus embolization during nephrectomy and tumor thrombectomy: critical analysis of the University of California-Los Angeles experience. J Urol (2008) 1.59
Interaction of IGF signaling and the androgen receptor in prostate cancer progression. J Cell Biochem (2006) 1.59
Performance status and cytoreductive nephrectomy: redefining management in patients with poor performance. Cancer (2008) 1.58
Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. Clin Cancer Res (2003) 1.57
Protective effects of plasma carotenoids on the risk of bladder cancer. J Urol (2006) 1.56
Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma. J Clin Oncol (2009) 1.55
Does primary androgen-deprivation therapy delay the receipt of secondary cancer therapy for localized prostate cancer? Eur Urol (2012) 1.55
CA9 gene: single nucleotide polymorphism predicts metastatic renal cell carcinoma prognosis. J Urol (2009) 1.54
Coevolution of prostate cancer and bone stroma in three-dimensional coculture: implications for cancer growth and metastasis. Cancer Res (2008) 1.53
Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival. Cancer (2008) 1.53
Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis. J Urol (2003) 1.52
Salvage-targeted kidney cancer therapy in patients progressing on high-dose interleukin-2 immunotherapy: the UCLA experience. Cancer J (2013) 1.52